Determining sensitivity to rapamycin and its analogues in breast cancer patients.
Witton
Caroline J
CJ
Endocrine Cancer Group, University of Glasgow, Glasgow, UK. cjw6r@clinmed.gla.ac.uk
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D051058:Oncogene Protein v-akt / Q000502:physiology; D011379:Prognosis; D011494:Protein Kinases / Q000502:physiology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology; D020123:Sirolimus / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D051058:Oncogene Protein v-akt; D011494:Protein Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human